Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Enriqueta Felip(Institut Català d'Ornitologia), S.-H. Lee(Samsung Medical Center), P. Tomasini(Inserm), Adlinda Alip(Harbin Medical University), N. Girard(Université de Versailles Saint-Quentin-en-Yvelines), Michael Gormley(Janssen (United States)), Yun Cheng(Jilin Province Tumor Hospital), Benjamin Besse(Institut Gustave Roussy), Raffaele Califano(The Christie NHS Foundation Trust), Mahesh Daksh(Harbin Medical University), C.G. Ferreira(BioClinica (United States)), Pongwut Danchaivijitr(Siriraj Hospital), Christophe Dooms(Chinese Academy of Medical Sciences & Peking Union Medical College), K. Prabhash(Tata Memorial Hospital), Y. Shinno, Antonio Passaro(European Institute of Oncology), Martin Schüler(German Cancer Research Center), G.-C. Chang(Chung Shan Medical University Hospital), H. Hayashi(Kindai University), J.M. Bauml(Janssen (United States)), Maya Gottfried(Meir Medical Center), Sadamu YAMAMOTO(Ehime University Hospital), E. Fennema(Harbin Medical University), Yu Jung Kim(Seoul National University Bundang Hospital), Alexander I. Spira(Virginia Cancer Specialists), Mehmet Alı Nahıt Şendur(Ankara Yıldırım Beyazıt University), Danny Nguyen(Harbin Medical University), J. Zhang(Janssen (United States)), James Chih‐Hsin Yang(National Taiwan University Hospital), K. Perdrizet(William Osler Health System), J.C. Curtin(Janssen (United States)), Byoung Chul Cho(Yonsei University), A.C.Z. Gelatti(Hospital São Lucas da PUCRS), Shaolin Lü(Shanghai Jiao Tong University), C.-C. Wang(Kaohsiung Chang Gung Memorial Hospital), S.M. Gadgeel, Daniil Stroyakovskiy(Shikoku Cancer Center), Marguerite Ennis(Janssen (United States)), Jerónimo Rafael Rodríguez‐Cid(Hospital Médica Sur), Scott Owen(McGill University Health Centre), L. Paz-Ares(Universidad Complutense de Madrid), K.-H. Lee(Chungbuk National University Hospital), Claire Martin(Instituto Alexander Fleming), S.-H.I. Ou(University of California, Irvine Medical Center), M.R. García Campelo(Complexo Hospitalario Universitario A Coruña), Seema Sethi(Janssen (United States)), Tingting Sun(Inner Mongolia Agricultural University), Amey C Panchal(Janssen (United Kingdom)), K. Azuma(Kurume University)
Cited by 81
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k